XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.0.1

Net Income (Loss) per Common Share (Tables)

9 Months Ended

Dec. 31, 2023

Net Income (Loss) per Common Share [Abstract]

Computations for Basic and Diluted Net Income (Loss) Per Common Share

The computations for basic and diluted net income (loss) per common share were as follows (in thousands, except share and per share amounts):

		Three Months Ended December 31,								Nine Months Ended December 31,
		2023				2022				2023				2022
Numerator:
Net income (loss) attributable to Roivant Sciences Ltd.		$	5,096,184			$	(352,014	)		$	4,500,041			$	(975,413	)
Denominator:
Weighted average shares outstanding, basic			800,587,716				713,319,399				776,759,728				703,054,773
Effect of dilutive common stock equivalents			43,873,969				—				47,550,285				—
Weighted average shares outstanding, diluted			844,461,685				713,319,399				824,310,013				703,054,773
Net income (loss) per common share, basic		$	6.37			$	(0.49	)		$	5.79			$	(1.39	)
Net income (loss) per common share, diluted		$	6.03			$	(0.49	)		$	5.46			$	(1.39	)

Potentially Dilutive Common Stock Equivalents Excluded from Computation of Diluted Net Income (Loss) per Common Share

As of December 31, 2023 and 2022, the following potentially dilutive common stock equivalents were excluded from the computation of diluted net income (loss) per common share because including them would have been anti-dilutive:

		December 31, 2023				December 31, 2022
Stock options and performance stock options			65,518,394				154,631,025
Restricted stock units and performance stock units (non-vested)			5,422,465				22,153,774
March 2020 CVARs(1)			17,548,368				32,011,996
November 2021 CVARs (non-vested)			359,730				3,609,021
Restricted common stock (non-vested)			238,059				730,522
Earn-Out Shares (non-vested)			3,080,387				3,080,387
Private Placement Warrants			—				10,214,365
Public Warrants			—				20,475,875
Other stock based awards and instruments issued			4,147,404				6,178,990

⁽¹⁾ Refer to Note 9, “Share-Based Compensation” for details regarding settlement of CVARs.

X

- References

No definition available.

+ Details

Name:	us-gaap_EarningsPerShareAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

+ Details

Name:	us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

+ Details

Name:	us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration